238 related articles for article (PubMed ID: 15912401)
1. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.
Melis M; Krenning EP; Bernard BF; Barone R; Visser TJ; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1136-43. PubMed ID: 15912401
[TBL] [Abstract][Full Text] [Related]
2. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney.
Rolleman EJ; Kooij PP; de Herder WW; Valkema R; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1854-60. PubMed ID: 17546456
[TBL] [Abstract][Full Text] [Related]
4. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.
De Jong M; Valkema R; Van Gameren A; Van Boven H; Bex A; Van De Weyer EP; Burggraaf JD; Körner M; Reubi JC; Krenning EP
J Nucl Med; 2004 Jul; 45(7):1168-71. PubMed ID: 15235063
[TBL] [Abstract][Full Text] [Related]
5. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice.
Vegt E; Melis M; Eek A; de Visser M; Brom M; Oyen WJ; Gotthardt M; de Jong M; Boerman OC
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):623-32. PubMed ID: 21170526
[TBL] [Abstract][Full Text] [Related]
6. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
7. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences.
Melis M; Krenning EP; Bernard BF; de Visser M; Rolleman E; de Jong M
Nucl Med Biol; 2007 Aug; 34(6):633-41. PubMed ID: 17707803
[TBL] [Abstract][Full Text] [Related]
8. Reducing renal uptake of radiolabeled peptides using albumin fragments.
Vegt E; van Eerd JE; Eek A; Oyen WJ; Wetzels JF; de Jong M; Russel FG; Masereeuw R; Gotthardt M; Boerman OC
J Nucl Med; 2008 Sep; 49(9):1506-11. PubMed ID: 18703613
[TBL] [Abstract][Full Text] [Related]
9. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
[TBL] [Abstract][Full Text] [Related]
10. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
12. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
15. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
16. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
de Jong M; Rolleman EJ; Bernard BF; Visser TJ; Bakker WH; Breeman WA; Krenning EP
J Nucl Med; 1996 Aug; 37(8):1388-92. PubMed ID: 8708781
[TBL] [Abstract][Full Text] [Related]
18. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
20. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
Rolleman EJ; Krenning EP; Van Gameren A; Bernard BF; De Jong M
J Nucl Med; 2004 Apr; 45(4):709-13. PubMed ID: 15073269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
